Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase EARLY_PHASE1 2Phase 4 1Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Disease 1

Interventions

Zoledronic Acid 14Leuprolide 9bicalutamide 6Triptorelin Pamoate 6Goserelin 6luprolide acetate gel depot 5enzalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Dutasteride 5fluciclovine F-18 3darolutamide 3Sodium Chloride 3Prednisone 3Magnetic Resonance Spectroscopy 3Flutamide 3Androgen Antagonists 3Abiraterone Acetate 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3cabazitaxel 2Propofol 2Prednisolone 2Lidocaine 2Gonadotropin-Releasing Hormone 2Finasteride 2Dexamethasone 2Desflurane 2Ciprofloxacin 2testosterone 17 beta-cypionate 1semaglutide 1polyethylene glycol 3350 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Prostatic Neoplasms × Positron Emission Tomography Computed Tomography × Clear all
NCT06479187 2025-11-05

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Brigham and Women's Hospital

Phase 4 Active not recruiting
20 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡